Everything below concerns actin-binding motif. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
The word bacteria ( ; sing.: bacterium) is the plural of the Neo-Latin bacterium, which is the romanisation of the Ancient Greek βακτήριον (baktḗrion), the diminutive of βακτηρία (baktēría), meaning 'staff' or 'cane', because the first ones to be discovered were rod-shaped. The word was first used to refer to bacteria in 1828.
=== Stationary compound selection === The polarity of the solute is crucial for the choice of stationary compound, which in an optimal case would have a similar polarity as the solute. Common stationary phases in open tubular columns are cyanopropylphenyl dimethyl polysiloxane, carbowax polyethyleneglycol, biscyanopropyl cyanopropylphenyl polysiloxane and diphenyl dimethyl polysiloxane. For packed columns more options are available.
The frog's brands were healed and readable within 24 hours of application, making this method nearly immediately effective as a tracking system. The branded area gradually loses its pigmentation such that older brands become almost completely transparent, increasing their legibility over time.
4-HO-MET binds to various serotonin receptors and is known to act as an agonist of the serotonin 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1A receptors. It is thought that the hallucinogenic effects of serotonergic psychedelics like 4-HO-MET are mediated by serotonin 5-HT2A receptor activation.
==== Seeds ==== The seeds can be removed from mature pods, cut, and cooked for consumption. In Nigeria, the seeds are prized for their bitter flavor; they are commonly added to sauces or eaten as a fried snack. The edible seed oil may be used in condiments or dressings. Ground, debittered moringa seed is suitable as a fortification ingredient to increase the protein, iron and calcium content of wheat flours.
Sources: en.wikipedia.org
An application of the Wittig-Still rearrangement in the context of natural product synthesis can be seen in Still's 1979 formal synthesis of the Cecropia juvenile hormone. The organotin-substituted ether that serves as the substrate for the rearrangement was readily prepared by bis-alkylation of the corresponding diol with iodomethyltributyltin. Treatment of this compound with two equivalents of n-butyllithium at low temperature resulted in transmetalation, initiating a double 2,3-sigmatropic rearrangement to give the bis-homoallylic alcohol product in 79% yield. Notably, this rearrangement is highly stereoselective with regard to the geometry of the trisubstituted olefins, giving exclusively the (Z,Z)-isomer shown.
Deputy Director of Adult Social Care, Care Quality Commission. For services to Adult Social Care. Dr. Meenakshi Nagpaul (Meena Thakur). General Practitioner, Honeypot Medical Centre and Clinical Director, Harrow East Primary Care Network. For services to the NHS. Jacqueline Neilson. Chief Executive Officer, Rain Rescue. For services to Animal Welfare. William Lambton Nicholson. Leader, Newbury Working Party Group. For services to Canal Restoration. June Edna Nicol-Dundas. Foster Carer, Fostering London. For services to Young People. Christopher Mansfeldt Norman. Chief Executive and Founder, GOOD Agency. For services to the Business and Charitable Sectors. John Norris. Chair, B&M Longworth (Edgworth) Ltd. For services to Innovation, to Sustainability and to International Trade. Lawrence John O'Halleron. Chair, Big Local Gateshead. For services to the community in Gateshead, Tyne and Wear. Leona O'Neil. Founder, The Boom Foundation. For services to Charitable Fundraising for People with Sarcoma. Harry Clive O'Neill. For charitable services to the community in County Down. Lanré Charles Olagoke. Founder, Art-Alive Arts Trust. For services to Charity and to Young People. David Edward Olney. Assistant Head Ukraine, Security Policy and Operations, Ministry of Defence. For services to Defence. Tori Pamela Anne Olphin. Chief Data Scientist and Head of Research, Thames Valley Police. For services to Technology in the Public Sector. Ehinor Otaigbe-Amedu. For services to Women in Greater Manchester. Lydia Jean Otter.
== Adenlylylation in Eukaryotes == Plants and yeasts have no known endogenous AMPylating enzymes, but animal genomes are endowed with a single copy of a gene encoding a Fic-domain AMPylase, that was likely acquired by an early ancestor of animals via horizontal gene transfer from a prokaryote. The human protein referred to commonly as FICD, had been previously identified as Huntingtin associated protein E (HypE; an assignment arising from a yeast two-hybrid screen, but of questionable relevance, as Huntingtin and HypE/FICD are localised to different cellular compartments). CG9523 Homologues in Drosophila melanogaster (CG9523) and C. elegans (Fic-1) have also received attention. In all animals FICD has a similar structure. It is a type II transmembrane domain protein, with a short cytoplasmic domain followed by membrane anchor that holds the protein in the endoplasmic reticulum (ER) and long C-terminal portion that resides in ER and encompasses tetratricopeptide repeats (TPRs) followed by a catalytic Fic domain.
== History == Roadie was founded by Marc Gorlin, a co-founder of Kabbage and founder of VerticalOne and Pretty Good Privacy, as a same-day and urgent delivery company in 2014. In January 2015, Roadie launched the first consumer to consumer (C2C) version of its app with a Series A funding round of $10 million. In February, Roadie announced a partnership with Waffle House to designate its restaurants "Roadie Roadhouses", offering a neutral meeting place for drivers and senders. Drivers receive free food and drink through the partnership. In May, late-night host Jimmy Kimmel discussed the Roadie-Waffle House relationship in an opening monologue on Jimmy Kimmel Live!. Roadie's driver network expanded significantly as a result. Roadie closed a Series B round of funding in June, raising $15 million, and its first business to business (B2B) app version launched that November. In 2015, Delta Air Lines signed an agreement with Roadie to deliver mishandled luggage, becoming Roadie’s first enterprise customer. Roadie launched a pilot program with Delta at Daytona Beach International Airport. Since then, the relationship has expanded to include over 70 airports around the United States and a first mile/last mile line haul relationship with Delta Cargo. In 2017, the company signed a deal with The Home Depot, also based in Atlanta, and in February 2019, closed a Series C round of funding. In October 2019, Roadie and Delta Cargo announced a partnership to create a same-day cross-country delivery offering, DASH Door-to-Door, the first of its kind from a U.S. passenger airline.
66th Academy Awards (1994): Best Supporting Actor, nomination, for What's Eating Gilbert Grape 77th Academy Awards (2005): Best Actor, nomination, for The Aviator 79th Academy Awards (2007): Best Actor, nomination, for Blood Diamond 86th Academy Awards (2014): Best Picture and Best Actor, nominations, for The Wolf of Wall Street 88th Academy Awards (2016): Best Actor, win, for The Revenant 92nd Academy Awards (2020): Best Actor, nomination, for Once Upon a Time in Hollywood 98th Academy Awards (2026): Best Actor, nomination, for One Battle After Another DiCaprio has won three Golden Globe Awards: Best Actor – Motion Picture Drama for The Aviator and The Revenant and Best Actor – Motion Picture Musical or Comedy for The Wolf of Wall Street, as well as a BAFTA Award and a Screen Actors Guild Award for Best Actor for The Revenant.
Sources: en.wikipedia.org
The process of acute inflammation is initiated by resident immune cells already present in the involved tissue, mainly resident macrophages, dendritic cells, histiocytes, Kupffer cells and mast cells. These cells possess surface receptors known as pattern recognition receptors (PRRs), which recognize (i.e., bind) two subclasses of molecules: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). PAMPs are compounds that are associated with various pathogens, but which are distinguishable from host molecules. DAMPs are compounds that are associated with host-related injury and cell damage. At the onset of an infection, burn, or other injuries, these cells undergo activation (one of the PRRs recognize a PAMP or DAMP) and release inflammatory mediators responsible for the clinical signs of inflammation. Vasodilation and its resulting increased blood flow causes the redness (rubor) and increased heat (calor). Increased permeability of the blood vessels results in an exudation (leakage) of plasma proteins and fluid into the tissue (edema), which manifests itself as swelling (tumor). Some of the released mediators such as bradykinin increase the sensitivity to pain (hyperalgesia, dolor). The mediator molecules also alter the blood vessels to permit the migration of leukocytes, mainly neutrophils and macrophages, to flow out of the blood vessels (extravasation) and into the tissue. The neutrophils migrate along a chemotactic gradient created by the local cells to reach the site of injury.
=== Awards === The restaurant chain was named "America's Most Promising Company" in 2011 by Forbes. In 2014, it again made this list coming in at number 6 for "America's Most Promising Companies". In 2017 the chain was named the number 9 favorite burger restaurant brand in America by The Harris Poll's annual EquiTrend Study. Crane was named one of "10 Executives to Watch" by Nation's Restaurant News during his tenure at the company.
Processing of food can decrease its nutritional density. The amount of nutrients lost depends on the food and processing method. For example, heat destroys vitamin C. Therefore, canned fruits possess less vitamin C than their fresh alternatives. The USDA conducted a study of nutrient retention in 2004, creating a table of foods, levels of preparation, and nutrition. New research highlighting the importance to human health of a rich microbial environment in the intestine indicates that abundant food processing (not fermentation of foods) endangers that environment.
The pancreas plays a vital role in the digestive system. It does this by secreting pancreatic juice, a fluid that contains digestive enzymes, into the duodenum, the first part of the small intestine that receives food from the stomach. These enzymes help to break down carbohydrates, proteins and lipids (fats). This is the exocrine role of the pancreas. The cells responsible for this are acinar cells arranged in clusters called acini. Secretions into the middle of the acinus accumulate in intralobular ducts, which drain to the main pancreatic duct, which drains directly into the duodenum. About 1.5–3 liters of fluid are secreted in this manner every day. The cells in each acinus are filled with granules containing the digestive enzymes. These are secreted in an inactive form termed zymogens or proenzymes. When released into the duodenum, they are activated by the enzyme enterokinase present in the lining of the duodenum. The proenzymes are cleaved, creating a cascade of activating enzymes.
The melanocortins are a family of neuropeptide hormones which are the ligands of the melanocortin receptors. The melanocortin system consists of melanocortin receptors, ligands, and accessory proteins. The genes of the melanocortin system are found in chordates. Melanocortins were originally named so because their earliest known function was in melanogenesis. It is now known that the melanocortin system regulates diverse functions throughout the body, including inflammatory response, fibrosis, melanogenesis, steroidogenesis, energy homeostasis, sexual function, and exocrine gland function. There are four endogenous melanocortin agonists which are derived from post-transcriptional processing of the precursor molecule proopiomelanocortin (POMC). They are adrenocorticotropic hormone (ACTH), α-melanocyte stimulating hormone (MSH), β-MSH, and γ-MSH. In addition to agonists which activate melanocortin receptors, there are two antagonists which inhibit receptor activity, agouti-signaling protein (ASIP) and agouti-related protein (AgRP). Lastly, the ligand β-defensin 3 acts as a neutral melanocortin receptor antagonist.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.